SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001798749-23-000013
Filing Date
2023-03-29
Accepted
2023-03-29 16:52:59
Documents
14
Period of Report
2023-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tmb-20230329x8k.htm   iXBRL 8-K 42173
2 EX-99.1 tmb-20230329xex99d1.htm EX-99.1 106333
3 GRAPHIC tmb-20230329xex99d1001.jpg GRAPHIC 5633
  Complete submission text file 0001798749-23-000013.txt   291788

Data Files

Seq Description Document Type Size
4 EX-101.SCH tmb-20230329.xsd EX-101.SCH 3124
5 EX-101.LAB tmb-20230329_lab.xml EX-101.LAB 16578
6 EX-101.PRE tmb-20230329_pre.xml EX-101.PRE 10780
8 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230329x8k_htm.xml XML 5040
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

IRS No.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 23775903
SIC: 2834 Pharmaceutical Preparations